Avid Bioservices, Inc. (CDMO)

NASDAQ: CDMO · IEX Real-Time Price · USD
16.19
-0.43 (-2.59%)
Feb 3, 2023, 4:00 PM EST - Market closed
-2.59%
Market Cap 1.01B
Revenue (ttm) 134.18M
Net Income (ttm) 118.25M
Shares Out 62.31M
EPS (ttm) 1.69
PE Ratio 9.58
Forward PE 81.30
Dividend n/a
Ex-Dividend Date n/a
Volume 451,486
Open 16.31
Previous Close 16.62
Day's Range 16.09 - 17.09
52-Week Range 11.30 - 22.83
Beta 1.85
Analysts Buy
Price Target 22.78 (+40.7%)
Earnings Date Mar 6, 2023

About CDMO

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides var... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1981
Employees 321
Stock Exchange NASDAQ
Ticker Symbol CDMO
Full Company Profile

Financial Performance

In 2022, CDMO's revenue was $119.60 million, an increase of 24.75% compared to the previous year's $95.87 million. Earnings were $127.67 million, an increase of 3747.86%.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for CDMO stock is "Buy." The 12-month stock price forecast is $22.78, which is an increase of 40.70% from the latest price.

Price Target
$22.78
(40.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Avid Bioservices (CDMO) Reports Q2 Loss, Tops Revenue Estimates

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 0% and 12.12%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2022 and Recent Developments

-- Recorded Second Quarter Revenue of $34.8 Million -- -- Signed $26 Million in Net New Business Orders Resulting in a Backlog of $147 Million, an Increase of 23% Year-Over-Year --

2 months ago - GlobeNewsWire

Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2023 After Market Close on December 6, 2022

TUSTIN, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient live...

2 months ago - GlobeNewsWire

Avid Bioservices Appoints Oksana Lukash as Vice President, People

TUSTIN, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient live...

2 months ago - GlobeNewsWire

Avid Bioservices to Participate in the Credit Suisse 31st Annual Healthcare Conference

TUSTIN, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient live...

3 months ago - GlobeNewsWire

Does Avid Bioservices (CDMO) Have the Potential to Rally 61% as Wall Street Analysts Expect?

The consensus price target hints at a 60.5% upside potential for Avid Bioservices (CDMO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

3 months ago - Zacks Investment Research

Avid Bioservices to Participate in RBC Global CDMO Conference

TUSTIN, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient liv...

4 months ago - GlobeNewsWire

Avid Bioservices Appoints Michael Alston, Jr. as Vice President, Operations

Accomplished Operations Professional Promoted from Role as Director of Project Engineering; Credited with Leading All of the Company's Ongoing Facility Expansion Projects Accomplished Operations Profe...

4 months ago - GlobeNewsWire

Avid Bioservices to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

TUSTIN, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient liv...

5 months ago - GlobeNewsWire

Avid Bioservices (CDMO) Beats Q1 Earnings and Revenue Estimates

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 33.33% and 7.92%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2022 and Recent Developments

-- Recorded First Quarter Revenue of $36.7 Million -- -- Signed $41 Million in Net New Business Orders and Ended the Quarter with a Record High  Backlog of $157 Million --

5 months ago - GlobeNewsWire

Avid Bioservices Appoints Pramthesh (Prem) Patel, Ph.D., as Vice President, Process Development for Mammalian Cell Business

Biopharmaceutical Executive with More than 30 Years of Experience With Top Global Big Pharma Companies GSK and Bristol Myers Squibb Biopharmaceutical Executive with More than 30 Years of Experience Wi...

5 months ago - GlobeNewsWire

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2023 After Market Close on September 6, 2022

TUSTIN, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient live...

5 months ago - GlobeNewsWire

Avid Bioservices Reports Financial Results for Fourth Quarter and Full Fiscal Year Ended April 30, 2022 and Recent Developments

-- Recorded Fourth Quarter and Full Fiscal Year Revenue of $31 Million and $120 Million, Respectively -- -- Signed $44 Million in Net New Business Orders and Ended the Quarter with a Record High Backl...

7 months ago - GlobeNewsWire

Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2022 After Market Close on June 29, 2022

TUSTIN, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient live...

8 months ago - GlobeNewsWire

Avid Bioservices, Inc. and CRB highlight efforts that enabled opening of first phase of new viral vector facility in California in only eight months

53,000-square-foot facility addresses unique demands of commercial-scale viral vector production COSTA MESA, Calif. , June 16, 2022 /PRNewswire/ -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated co...

8 months ago - PRNewsWire

Avid Bioservices Announces Launch of Analytical and Process Development Suites Within New, World-Class Viral Vector Development and Manufacturing Facility

AD/PD Laboratories Open Exactly Eight Months After Announced Plans to Build Viral Vector Facility

8 months ago - GlobeNewsWire

Avid Bioservices Announces Further Expansion of Process Development Capacity for Mammalian Cell Business

New Laboratories Have Potential to Support an Additional $20 Million in Annual Process Development Revenue, Doubling Current Mammalian Cell Process Development Capacity

8 months ago - GlobeNewsWire

Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Forum

TUSTIN, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient liv...

11 months ago - GlobeNewsWire

Avid Bioservices (CDMO) Q3 Earnings and Revenues Top Estimates

Avid Bioservices (CDMO) delivered earnings and revenue surprises of 80% and 12.53%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2022 after Market Close on March 8, 2022

TUSTIN, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient liv...

1 year ago - GlobeNewsWire

Avid Bioservices (CDMO) Stock Sinks As Market Gains: What You Should Know

Avid Bioservices (CDMO) closed the most recent trading day at $21.25, moving -1.16% from the previous trading session.

1 year ago - Zacks Investment Research

Avid Bioservices (CDMO) Gains But Lags Market: What You Should Know

Avid Bioservices (CDMO) closed at $18.97 in the latest trading session, marking a +0.53% move from the prior day.

1 year ago - Zacks Investment Research

Avid Bioservices Announces Official Opening of Second Downstream Processing Suite Within Myford North Facility

Milestone Marks Completion of First Phase of Two-Part Myford Facility Expansion; First Customer Project to Begin in New Downstream Processing Suite in Coming Month Milestone Marks Completion of First ...

1 year ago - GlobeNewsWire

Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength

3 Biopharma Stocks Displaying Relative Strength Heading Into 2022

Other symbols: GILDREGN
1 year ago - Zacks Investment Research